Novo Nordisk Faces Investor Skepticism Despite CEO’s Turnaround Efforts

Despite Chief Executive Mike Doustdar’s claims that the market is underestimating the long-term potential of the company’s pharmaceutical pipeline, investors remain cautious about future growth prospects.

1 Sept, 14:06 — 1 Sept, 14:06

Post Share

Sources

Showing 1 of 1 sources

NYTMostly Factual1d ago

Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future

Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.

By Eshe Nelson

Read full article →

Novo Nordisk Faces Investor Skepticism Despite CEO’s Turnaround Efforts

Sources

Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future

Related Stories

Brazilian Presidential Race Tightens as Lula and Bolsonaro Approach Virtual Tie

Bank of America Raises Microsoft Price Target Amid Shifting Credit Markets

Chevron Announces $7 Billion Plan to Double Oil Production in Venezuela

Daktronics Shares Surge on Strong First-Quarter Earnings Beat